Testing a new drug for advanced HER2-positive Paget's disease
Treatments studied
Part of Cancer clinical trials.
This trial tests an investigational drug called Disitamab Vedotin for people with advanced Paget's disease that tests positive for HER2. It aims to see if the drug can shrink tumors or improve skin lesions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have Paget's disease (mammary or extramammary) that is advanced and confirmed by biopsy, with HER2 positive (score 1+ or higher).
- You must be in good enough health to perform daily activities (ECOG score 0 or 1).
- You must have at least one measurable tumor on a CT scan or skin lesions that can be evaluated.
- Your blood counts, liver, and kidney function must meet certain minimum levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs: disitamab vedotin (which attacks cancer cells with a certain protein) and bicalutamide (which blocks male hormones that can fuel cancer growth). It is for people with Paget's disease that has spread or cannot be removed, and whose cancer cells have specific protein markers called HER2 and AR.
This trial tests RC48, an antibody-drug treatment, for people with advanced breast cancer that cannot be cured or removed, specifically HER2-low (or HER2-ultralow) tumors. It may help by targeting cancer cells with this “HER2-low” trait while limiting spread in the body.
This trial tests two drugs, disitamab vedotin and trastuzumab, for people with HER2-positive stomach or gastroesophageal junction cancer that has spread or come back after at least one prior treatment. The goal is to see if this combination can help shrink tumors.
This trial tests a new combination of drugs (DV plus pertuzumab, with or without toripalimab) given before surgery for HER2-positive breast cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This trial tests a new combination of drugs (RC48, sintilimab, and SOX chemotherapy) for people with stomach or gastroesophageal junction cancer that cannot be removed by surgery, has not been treated before, and has a specific HER2 score (1+ or 2+). The goal is to shrink the tumor enough to possibly allow surgical removal.
This trial tests a combination of two drugs (disitamab vedotin and toripalimab) followed by chemotherapy before surgery for people with a specific type of breast cancer that is hormone receptor-positive and HER2-low. The goal is to see if this treatment can shrink the tumor and improve outcomes.
Hear when a new Mammary or Extramammary Paget's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.